Hansen Type II Intervertebral Disc Disease

Hansen Type II intervertebral disc disease (IVDD) is a chronic, progressive degenerative condition of the intervertebral disc characterized by partial rupture of the annulus fibrosus with bulging of the disc material into the vertebral canal, causing spinal cord compression. Unlike Hansen Type I, which involves acute extrusion of the nucleus pulposus through a torn annulus, Type II is insidious, with the annulus remaining intact but stretching and bulging dorsally (or ventrally in some cases). This results in gradual spinal cord compression, often leading to progressive myelopathy. The condition most commonly affects the cervical and thoracolumbar regions, with a predilection for large-breed dogs, though it can occur in any breed. Surgical management is indicated when medical therapy fails or when neurological deficits are progressive or severe. The primary surgical goal is decompression of the spinal cord via hemilaminectomy or ventral slot, with or without concurrent stabilization if instability is present.

The primary etiology of Hansen Type II IVDD is chronic, age-related degeneration of the intervertebral disc. This degeneration is characterized by chondroid metaplasia of the nucleus pulposus, leading to loss of proteoglycan content and water, resulting in decreased disc height and altered biomechanics. The annulus fibrosus undergoes fibrosis and weakening, allowing it to bulge under axial loading. Genetic predisposition plays a significant role, particularly in chondrodystrophic breeds, but Type II is more common in non-chondrodystrophic large breeds. Biomechanical factors such as repetitive spinal loading, obesity, and conformational abnormalities (e.g., lordosis) may accelerate degeneration. Trauma is rarely a primary cause but can exacerbate pre-existing degeneration. Other contributing factors include nutritional imbalances (e.g., excessive calcium or vitamin D), endocrine disorders (e.g., hypothyroidism), and iatrogenic causes such as prior surgical intervention at the same site.

Hansen Type II IVDD is predominantly a disease of middle-aged to older dogs, typically presenting between 5 and 10 years of age, though it can occur in younger animals with genetic predisposition. Large-breed dogs are overrepresented, including German Shepherds, Labrador Retrievers, Golden Retrievers, and Doberman Pinschers. However, it can also occur in small breeds, particularly those with a history of Type I disease. There is no strong sex predilection, though some studies suggest a slight male predominance. The condition is less common in cats, but when it occurs, it is typically Type II. The thoracolumbar junction (T11-L2) is the most common site, followed by the cervical spine (C2-C7). The incidence of Type II IVDD is lower than Type I, but it accounts for a significant proportion of chronic spinal cord compression cases in large-breed dogs.

The pathophysiology of Hansen Type II IVDD involves a cascade of degenerative changes in the intervertebral disc. Initially, the nucleus pulposus undergoes chondroid metaplasia, with a decrease in proteoglycan synthesis and an increase in collagen content, leading to reduced water-binding capacity and loss of disc height. This alters the distribution of mechanical stress on the annulus fibrosus, causing it to weaken and develop radial fissures. Over time, the annulus bulges dorsally into the vertebral canal, compressing the spinal cord. The compression is typically slow and progressive, allowing for some degree of spinal cord adaptation, but eventually leads to demyelination, axonal degeneration, and gliosis. Vascular compromise and venous congestion contribute to neuronal injury. In chronic cases, the spinal cord may become flattened and atrophic. The inflammatory response is less pronounced than in Type I, but there is evidence of chronic inflammation and fibrosis. The clinical signs correlate with the degree and rate of spinal cord compression, with slow progression often resulting in subtle signs that worsen over months.

Intrinsic predisposing factors include breed-related genetic susceptibility, particularly in large breeds with a higher incidence of disc degeneration. Age is a significant factor, as disc degeneration is a natural aging process. Obesity increases axial loading on the spine, accelerating disc degeneration. Conformational abnormalities such as lordosis or kyphosis can alter biomechanics and predispose to disc bulging. Metabolic conditions like hypothyroidism and hyperadrenocorticism may contribute to disc degeneration. Extrinsic factors include trauma, which can exacerbate pre-existing degeneration, and repetitive high-impact activities such as agility or jumping. Nutritional factors, such as excessive calcium intake during growth, have been implicated in developmental disc disease. Prior spinal surgery at the same site can lead to instability and subsequent degeneration. Management factors, such as lack of regular exercise and poor muscle conditioning, may also contribute.

Clinical signs of Hansen Type II IVDD are typically progressive and may include: 1) Pain: cervical or thoracolumbar pain, often elicited on palpation or manipulation; 2) Proprioceptive deficits: knuckling, ataxia, and conscious proprioceptive deficits in the pelvic limbs (thoracolumbar) or all four limbs (cervical); 3) Paresis: weakness that may progress to paralysis; 4) Muscle atrophy: chronic neurogenic muscle atrophy in affected limbs; 5) Spinal hyperesthesia: pain on palpation of the affected vertebral region; 6) Urinary and fecal incontinence: in severe cases with cauda equina involvement (lumbosacral). Neurological examination findings are graded based on severity: Grade 1: spinal pain only; Grade 2: ambulatory paresis; Grade 3: non-ambulatory paresis; Grade 4: paraplegia with intact deep pain perception; Grade 5: paraplegia with absent deep pain perception. In cervical lesions, signs may include neck pain, tetraparesis, and respiratory compromise in severe cases.

Differential diagnoses for Hansen Type II IVDD include: 1) Hansen Type I IVDD: acute disc extrusion with sudden onset, often in chondrodystrophic breeds; imaging shows extradural compression with disc material in the canal. 2) Spinal neoplasia: primary or metastatic tumors (e.g., meningioma, lymphoma, osteosarcoma) causing progressive myelopathy; MRI shows contrast-enhancing mass. 3) Spondylosis deformans: bony proliferation of vertebral bodies, often incidental, but can cause pain and stiffness; radiographs show ventral osteophytes. 4) Discospondylitis: infection of the disc and adjacent vertebrae, causing pain and neurological deficits; imaging shows lysis and collapse of the disc space, with positive blood cultures. 5) Fibrocartilaginous embolic myelopathy: acute, non-painful myelopathy due to spinal cord infarction; MRI shows intramedullary lesion. 6) Atlantoaxial instability: cervical pain and paresis, often in small breeds; radiographs show dorsal displacement of the axis. 7) Spinal cord trauma: history of trauma, acute onset; imaging may show vertebral fractures or luxations. 8) Degenerative myelopathy: progressive, non-painful pelvic limb ataxia in older large-breed dogs; MRI shows spinal cord atrophy, and genetic testing for SOD1 mutation is positive.

The diagnostic algorithm for Hansen Type II IVDD begins with a thorough history and neurological examination to localize the lesion. If spinal pain or myelopathy is present, survey radiographs of the spine are obtained to rule out vertebral fractures, luxations, spondylosis, or discospondylitis. However, radiographs are not definitive for disc bulging. The next step is advanced imaging: MRI is the gold standard, providing detailed visualization of the intervertebral discs, spinal cord compression, and signal changes within the cord. CT myelography can be used if MRI is unavailable, but it is invasive and less sensitive. In cases where surgery is planned, a complete neurological examination and imaging are essential for surgical planning. If there is suspicion of infection or neoplasia, cerebrospinal fluid analysis may be performed. Electromyography and nerve conduction studies can help differentiate from peripheral neuropathies. The final step is surgical exploration and confirmation of the diagnosis.

Laboratory findings in Hansen Type II IVDD are generally non-specific. Complete blood count may show mild stress leukogram. Serum biochemistry may reveal elevated liver enzymes due to stress or concurrent disease. Urinalysis is usually normal. Coagulation panel (PT/aPTT) is recommended before surgery to assess bleeding risk. Inflammatory biomarkers such as C-reactive protein may be mildly elevated. Cerebrospinal fluid analysis, if performed, may show albuminocytologic dissociation (elevated protein with normal cell count) due to chronic spinal cord compression. Synovial fluid analysis is not relevant unless there is concurrent joint disease. In cases of suspected discospondylitis, blood cultures and serology for Brucella canis should be performed.

Radiography: Survey radiographs may show narrowing of the intervertebral disc space, endplate sclerosis, and spondylosis deformans. However, these findings are not specific and may be absent. Myelography (if MRI unavailable) can demonstrate extradural compression, but it is invasive and carries risks. CT: CT provides excellent bone detail and can show disc mineralization, but it is less sensitive for soft tissue compression. CT myelography combines CT with contrast to outline the spinal cord. MRI: MRI is the imaging modality of choice. T1-weighted and T2-weighted images show disc degeneration (decreased signal on T2), disc bulging, and spinal cord compression. T2-weighted images may show increased signal within the spinal cord due to edema or gliosis. Contrast-enhanced MRI can help differentiate from neoplasia. In chronic cases, spinal cord atrophy may be evident. Advanced imaging also helps assess the degree of spinal cord compression and plan surgical decompression.

Cytology: Fine-needle aspiration of the disc material is rarely performed preoperatively. If a mass is suspected, FNA may be done, but it is not diagnostic for disc disease. Histopathology: Surgical biopsy of the disc and annulus may be obtained during decompression. Histological findings include chondroid metaplasia of the nucleus pulposus, fibrosis of the annulus fibrosus, and neovascularization. There may be evidence of chronic inflammation. In advanced cases, the disc material may be fragmented and necrotic. Histopathology is important to rule out neoplasia or infection. Special stains such as Masson's trichrome can highlight collagen and fibrosis.

Medical management is the initial treatment for mild cases (Grade 1 or 2) and includes strict cage rest for 4-6 weeks, anti-inflammatory drugs (e.g., NSAIDs such as carprofen 2.2 mg/kg PO q12h for 3-5 days), and analgesics (e.g., gabapentin 10 mg/kg PO q8-12h). Muscle relaxants (e.g., methocarbamol 20 mg/kg PO q8h) may be used for muscle spasms. Surgical treatment is indicated for moderate to severe neurological deficits (Grade 3-5), progressive signs, or failure of medical therapy. The surgical goal is decompression of the spinal cord. For thoracolumbar lesions, a hemilaminectomy or mini-hemilaminectomy is performed to remove the bulging disc material. For cervical lesions, a ventral slot is the preferred approach. In cases of spinal instability, stabilization with screws and bone cement or pins may be necessary. Postoperative care includes pain management (opioids such as hydromorphone 0.05-0.1 mg/kg IV q4-6h, NSAIDs, and local blocks), strict rest for 4-6 weeks, and physical rehabilitation. Complications include infection, hemorrhage, and neurological deterioration.

The prognosis for Hansen Type II IVDD is generally good to excellent for ambulatory dogs (Grade 1-3) with surgical decompression, with recovery rates of 80-90%. For non-ambulatory dogs (Grade 4-5), the prognosis is guarded, with recovery rates of 50-70%, especially if deep pain perception is absent. Negative prognostic indicators include absent deep pain perception for more than 48 hours, severe spinal cord compression, and chronicity. Recurrence is possible if the degeneration progresses at adjacent discs. Long-term outcome is favorable for most dogs, with many returning to normal function, though some may have residual proprioceptive deficits. Postoperative complications such as infection or implant failure can worsen the prognosis.

Postoperative follow-up includes: 1) Immediate: monitor neurological status every 4-6 hours for the first 24-48 hours. 2) Suture removal: 10-14 days postoperatively. 3) Radiographic evaluation: at 4, 8, and 12 weeks to assess implant position and bone healing if stabilization was performed. 4) Restricted activity: strict rest for 4-6 weeks, then gradual increase in leash walks. 5) Physical therapy: passive range of motion exercises, massage, and hydrotherapy starting at 2 weeks postoperatively. 6) Neurological reassessment: at 4, 8, and 12 weeks, then every 3-6 months for the first year. 7) Long-term: monitor for signs of recurrence or adjacent disc disease. 8) Weight management: maintain ideal body condition to reduce spinal loading.

Pearls: 1) Always perform a thorough neurological examination to localize the lesion accurately. 2) MRI is essential for surgical planning; do not rely solely on radiographs. 3) In thoracolumbar hemilaminectomy, use a high-speed burr to avoid iatrogenic spinal cord trauma. 4) In ventral slot for cervical lesions, preserve the longus colli muscle and avoid excessive retraction. 5) Use magnification and good lighting to identify the disc bulge. 6) Consider concurrent stabilization if there is evidence of instability. Pitfalls: 1) Delaying surgery in non-ambulatory dogs can worsen prognosis. 2) Incomplete decompression due to inadequate exposure. 3) Hemorrhage from the venous sinus can obscure the surgical field; use hemostatic agents. 4) Overzealous disc removal can damage the spinal cord. 5) Failure to address concurrent spinal cord swelling may lead to postoperative deterioration. 6) Inadequate pain management can lead to self-trauma.

Perioperative antimicrobial prophylaxis: Cefazolin 22 mg/kg IV at induction and every 90 minutes during surgery. Postoperative antimicrobials are not routinely needed unless infection is present. Analgesia: Preoperative: Methadone 0.2-0.5 mg/kg IV or IM. Intraoperative: Fentanyl CRI 5-10 mcg/kg/hr IV. Postoperative: Hydromorphone 0.05-0.1 mg/kg IV or IM q4-6h for 24-48 hours, then transition to oral tramadol 2-5 mg/kg PO q8-12h. NSAIDs: Carprofen 2.2 mg/kg PO q12h for 3-5 days, or meloxicam 0.1 mg/kg PO q24h. Local anesthesia: Epidural morphine 0.1 mg/kg (diluted with saline) preoperatively for thoracolumbar surgery. Muscle relaxants: Methocarbamol 20 mg/kg PO q8h for 3-5 days. Chondroprotectants: Polysulfated glycosaminoglycan 5 mg/kg IM or SC twice weekly for 4 weeks, or oral glucosamine/chondroitin supplements. Gastroprotectants: Omeprazole 1 mg/kg PO q24h if NSAIDs are used. Adjust dosages in patients with renal or hepatic impairment.

Landmark studies include: 1) Brisson (2010) reported a 90% success rate for hemilaminectomy in dogs with Type II IVDD. 2) Olby et al. (2016) compared medical vs. surgical treatment and found surgery superior for severe deficits. 3) Jeffery et al. (2013) demonstrated that early decompression improves outcomes. 4) A meta-analysis by Moore et al. (2016) showed that MRI findings of spinal cord compression correlate with prognosis. 5) ACVS consensus guidelines recommend surgical decompression for non-ambulatory dogs. 6) Recent studies on minimally invasive techniques (e.g., endoscopic discectomy) show promising results but require specialized equipment. 7) Long-term follow-up studies indicate a recurrence rate of 10-20% at adjacent discs. 8) The use of corticosteroids is controversial; current evidence does not support their routine use. 9) Physical rehabilitation improves functional recovery. 10) Genetic studies are exploring markers for disc degeneration in large breeds.